This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Insight On MediciNova's MN-166 Mechanism Of Action Reported In Proceedings Of The National Academy Of Sciences

SAN DIEGO, July 7, 2010 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences (PNAS) USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders. The research was lead by Dr. Elias Lolis at Yale University, and the article identifies Macrophage Migration Inhibitor Factor (MIF) as a potent and selective target for ibudilast which likely accounts for some of the drug's anti-inflammatory and neuroprotective action. MIF is one of the oldest-known pro-inflammatory cytokines thought to be involved in a number of serious medical conditions including severe systemic inflammation, autoimmunity and neuronal death and dysfunction following spinal cord injury. 

In the article, Dr. Lolis and collaborators describe the differentiated means by which ibudilast and its closely related novel analog, AV1013, inhibit MIF action. The investigators applied biological, biochemical and physical-chemical approaches demonstrating that ibudilast and AV1013 inhibit MIF's enzymatic and biologic action by interacting with the MIF protein at a region that is not considered the "active" site. Rather, they result in a change in the protein structure and subsequent inhibition of MIF activity. Accordingly, the identification that MN-166 and AV1013 selectively and potently inhibit MIF provides insights to mechanisms whereby these drug candidates may provide benefit in multiple sclerosis, neuropathic pain and drug addiction; neurological conditions that may share common disease pathways. Moreover, ibudilast has shown efficacy in animal models and early-stage human clinical trials in these conditions.

Dr. Lolis' lab at Yale University is one of the leading research groups studying MIF biochemistry and biology and his group and collaborators spent nearly three years developing the approaches and obtaining the data presented in the PNAS article. He noted that, "Our studies reveal an allosteric site explaining the mechanism of action of these drug candidates and additionally identifying a new potential site for drug discovery targeting MIF-mediated diseases."  Dr. Kirk Johnson, MediciNova's Chief Scientific Officer and a co-author of the article, added, "These research findings highlight the unique character of these drug candidates and, given the correlation of MIF inhibition and clinical drug levels, aid our understanding of MN-166 clinical action." MN-166 has completed a phase 2 proof-of-concept trial in which its potential neuroprotective utility in progressive multiple sclerosis was first illustrated and recently reported in Neurology. Additionally, MN-166 was studied in a phase 1b/2a trial in chronic neuropathic pain and is currently being evaluated in a phase 1b/2a trial for opioid withdrawal in heroin addicts. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova noted that, "We are pleased with the research and clinical development progress with MN-166 and analogs and hope to expand clinical testing with corporate partner participation."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs